Balaxi Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Balaxi Pharmaceuticals (BALAXI) reported revenue ₹74 Cr and net profit ₹1 Cr — revenue -1.3% YoY. Analyse BALAXI shareholding pattern to track promoter, FII and institutional holdings.
BALAXI Quarterly Results — Revenue, Profit & EPS Highlights
Balaxi Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit BALAXI share price.
- Revenue of ₹74 Cr in Mar 2026 (-7.5% vs Jun 2026, -1.3% vs Mar 2025)
- Net Profit of ₹1 Cr in Mar 2026 (+0.0% vs Jun 2026, -88.9% vs Mar 2025)
- EBITDA of ₹3 Cr in Mar 2026 (-25.0% vs Jun 2026)
- Earnings Per Share of ₹0.11 in Mar 2026 (-54.2% vs Jun 2026)
Balaxi Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BALAXI quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 74 | 80 | 58 | 75 | 69 | -7.5% | -1.3% |
| Net Profit (₹ Cr) | 1 | 1 | 0 | 9 | 0 | - | - |
| EBITDA (₹ Cr) | 3 | 4 | 3 | 11 | 2 | - | - |
| EPS (₹) | 0.11 | 0.24 | 0.04 | 1.56 | 0.05 | - | - |
| Operating Margin (%) | 0.0% | 6.0% | 2.0% | 16.0% | 6.0% | - | - |
BALAXI Share Price Trend — 1-Year Movement Across Quarterly Results
Balaxi Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View Balaxi Pharmaceuticals yearly highs lows for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BALAXI vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Balaxi Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores